Clinical trials: Intracranial Pathology
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at 5 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm…
- Trial name
- CONSCIOUS-2 (NCT00558311)
- Testing
- Clazosentan
- Where
- 117 sites in United States, Australia and 27 more
- Volunteers
- 1,157 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Intracerebral Hemorrhage (ICH)
Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single escalating dose and repeated doses of CN-105 in healthy adult participants. There will be about 48 subjects, 36 active and 12 placebo.
- Trial name
- NCT02670824
- Testing
- CN-105
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AegisCN LLC
Intracerebral Hemorrhage, Stroke, Acute
A Study to Test the SENSE Device in Patients With Intracranial Hemorrhage
The purpose of this research study is to find out whether a device for monitoring bleeding in patients with acute hemorrhagic stroke will show similar findings as CT scans performed to evaluate the stroke.
- Conditions
- Intracerebral Hemorrhage, Stroke, Acute, Stroke Hemorrhagic
- Trial name
- NCT03038087
- Testing
- SENSE Device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sense Diagnostics, LLC
Cerebral Ischemia
Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)
Safety and effect of SANGUINATE on patients DCI following SAH.
- Trial name
- NCT02323685
- Testing
- SANGUINATE™
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Prolong Pharmaceuticals
Postoperative Complications, Memory Disorders
A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events
The purpose of this study is to determine if the use of a carbon dioxide lavage device (CarboJet) to clean bone surfaces during total knee surgery decreases intraoperative embolic events when compared with standard orthopedic…
- Trial name
- NCT00736125
- Testing
- pulsatile saline lavage, carbon dioxide lavage
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kinamed Incorporated
Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain
Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with Hereditary Cystatin C Amyloid Angiopathy (HCCAA).
- Conditions
- Hereditary Cystatin C Amyloid Angiopathy (HCCAA), Hemorrhage Brain, Hemorrhage Cerebral
- Trial name
- HCCAA (NCT07716865)
- Testing
- NACA
- Where
- Iceland
- Volunteers
- 15 people
- Sponsor
- Arctic Therapeutics
Stroke, Ischemic, Infarction, Middle Cerebral Artery
Testing of Identification Markers for Stroke
Stroke is the third leading cause of death and the first cause of physical disability and dementia worldwide. Ischemic stroke caused by large vessel occlusion (LVO) is responsible for the vast majority of deaths and disabilities.
- Conditions
- Stroke, Ischemic, Infarction, Middle Cerebral Artery, Infarction, Anterior Circulation, Brain
- Trial name
- TIME (NCT04292600)
- Testing
- POCKiT diagnostics' algorithm for LVO detection
- Where
- 3 sites in United States
- Volunteers
- 383 people
- Sponsor
- POCKiT diagnostics Ltd
Hydrocephalus, Hydrocephalus in Children
A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)
Aqueduct's Smart External Drain (SED) will be compared to the current gold standard for temporary CSF management in a hospital setting.
- Conditions
- Hydrocephalus, Hydrocephalus in Children, Tumor, Brain, Subarachnoid Hemorrhage
- Trial name
- NCT03471702
- Testing
- Smart External Drain - SED
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aqueduct Critical Care
Intracranial Hemorrhages, Traumatic Brain Injury
Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage
This study is a two-stage, pivotal, prospective, non-randomized, multi-center, within patient comparison of the SENSE device and the standard diagnostic test, head CT scan in patients with a diagnosis of primary spontaneous ICH…
- Trial name
- NCT04642443
- Testing
- SENSE Device
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Sense Diagnostics, LLC
Alzheimer's Disease, Mild Cognitive Impairment
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia
- Trial name
- NCT01465360
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Exonhit
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
This trial is conducted in North America, Europe, Asia and Oceania. The purpose of this study is to evaluate safety and efficacy of Recombinant Factor VIIa in patients with acute intracerebral bleeding.
- Trial name
- NCT00426803
- Testing
- activated recombinant human factor VII
- Where
- 15 sites in Australia, Austria and 13 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Subdural Hematoma
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma…
- Trial name
- EMBOLISE (NCT04402632)
- Testing
- Surgical Management, Onyx™ Liquid Embolic System (LES) Embolization, Observation Only
- Where
- 49 sites in United States
- Volunteers
- 600 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Middle Cerebral Artery Stroke
The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)
The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT).
- Trial name
- NCT00401310
- Testing
- Comparator: MK0724
- Volunteers
- 150 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Acquired Bleeding Disorder, Intracerebral Haemorrhage
Factor VIIa in Acute Intracerebral Haemorrhage
This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.
- Trial name
- NCT00266006
- Testing
- eptacog alfa (activated)
- Where
- Japan
- Volunteers
- 90 people
- Sponsor
- Novo Nordisk A/S
Subarachnoid Hemorrhage
Efficacy and Safety Assessment for a New UV-protected Pump Infusion Line in Intravenous Infusion Therapy
To verify the efficacy and safety of Original Perfusor Line (Art.No.8723017) in infusion therapy in Patients with light sensitive drug infusion.
- Trial name
- NCT04309708
- Testing
- Nimodipine pump infusion
- Where
- 5 sites in China
- Volunteers
- 300 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Chronic Subdural Hematomas
PHIL™ Middle Meningeal Artery Embolization for First-Line Treatment of Chronic Subdural Hematoma IDE Trial
This is a prospective, randomized, controlled, open-label, blinded endpoint (PROBE) clinical investigation in which patients with non-emergent chronic subdural hematoma (cSDH) requiring treatment will be randomized (1:1) to…
- Trial name
- PHILFIRST (NCT07576998)
- Testing
- PHIL™ (Precipitating Hydrophobic Injectable Liquid), Surgical evacuation
- Volunteers
- 475 people
- Sponsor
- Microvention-Terumo, Inc.
Traumatic Brain Injury, Intracranial Hemorrhages
Usability Study of CEREBO® - A Novel Non-invasive Intracranial Bleed Detector
Traumatic Brain Injury (TBI) is the leading cause of death and disability across the globe. Time from injury to treatment is the most critical factor that determines the patient's recovery.
- Trial name
- NCT05340114
- Testing
- CEREBO®
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bioscan Research Pvt. Ltd.
Stroke, Acute, Intracranial Hemorrhages
Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet
The primary objective is to evaluate the safety and tolerability of single ascending dose of Y-2 sublingual tablets in healthy male and female adult subjects.
- Trial name
- NCT03495206
- Testing
- Y-2(Edaravone And Borneol) Sublingual Tablet
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Yantai YenePharma Co., Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
- Trial name
- CONSCIOUS-1 (NCT00111085)
- Testing
- Clazosentan 1 mg/h, Clazosentan 5 mg/h, Clazosentan 15 mg/h
- Where
- 16 sites in United States, Canada
- Volunteers
- 413 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.